Share on StockTwits

Durata Therapeutics (NASDAQ:DRTX) CEO Paul R. Edick purchased 3,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, June 12th. The stock was purchased at an average cost of $15.23 per share, with a total value of $45,690.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Durata Therapeutics (NASDAQ:DRTX) opened at 16.16 on Tuesday. Durata Therapeutics has a 1-year low of $6.70 and a 1-year high of $17.20. The stock’s 50-day moving average is $15.29 and its 200-day moving average is $13.48. The company’s market cap is $430.5 million.

Durata Therapeutics (NASDAQ:DRTX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.62) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.64) by $0.02. Analysts expect that Durata Therapeutics will post $-2.39 EPS for the current fiscal year.

A number of analysts have recently weighed in on DRTX shares. Analysts at Roth Capital raised their price target on shares of Durata Therapeutics from $21.00 to $24.00 in a research note on Tuesday, May 27th. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Durata Therapeutics from $19.00 to $23.00 in a research note on Tuesday, May 27th. They now have an “outperform” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Durata Therapeutics from $14.00 to $15.00 in a research note on Tuesday, May 27th. They now have a “hold” rating on the stock. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Durata Therapeutics presently has an average rating of “Buy” and a consensus price target of $19.38.

Durata Therapeutics, Inc is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.